Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy

被引：6

作者：

Corbelli, JC

Bullano, MF

Willey, VJ

Cziraky, MJ

Corbelli, ME

Waugh, W

机构：

[1] Buffalo Cardiol & Pulm Associates, Williamsville, NY 14231 USA

[2] Hlth Core Inc, Newark, DE USA

[3] WellPoint Pharm Management, Canoga Pk, CA USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2002年 / 90卷 / 12期

关键词：

D O I：

10.1016/S0002-9149(02)02880-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients stabilized on statin therapy who were switched from gemfibrozil to fenotibrate due to inadequate lipid response or adverse effects experienced significant improvements in total cholesterol, triglycerides, high-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol levels, with no significant change in low-density lipoprotein cholesterol. Patients did not have any clinically significant elevations in liver function tests or creatine phosphokinase levels while on either-fibrate in combination with a statin.

引用

页码：1388 / +

页数：5

共 7 条

[1] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[2]

Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014

[3] Triglyceride concentration and ischemic heart disease - An eight-year follow-up in the Copenhagen Male Study [J].

Jeppesen, J ;

Hein, HO ;

Suadicani, P ;

Gyntelberg, F .

CIRCULATION, 1998, 97 (11) :1029-1036

[4] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Fye, CL ;

Anderson, JW ;

Elam, MB ;

Faas, FH ;

Linares, E ;

Schaefer, EJ ;

Schectman, G ;

Wilt, TJ ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) :410-418

[5]

Rubins HB, 2001, CIRCULATION, V103, P2828

[6] Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study [J].

Schlesinger, Z ;

Vered, Z ;

Friedenson, A ;

Reisin, L ;

Jafari, J ;

Flieb, T ;

Sclarovsky, S ;

Friedman, Y ;

Ostfeld, B ;

Solodky, A ;

Abinader, E ;

Rochfleish, S ;

Palant, A ;

Schneider, H ;

Rosenfeld, T ;

Khalid, S ;

Wolfson, E ;

Kishon, Y ;

Narinsky, R ;

Rotzak, R ;

Davidov, A ;

Levine, G ;

Zahavi, I ;

Vitrai, J ;

Diker, D ;

Pelled, B ;

Pardu, J ;

Galamidi, J ;

Majadla, R ;

Laniado, S ;

Sherf, L ;

Braun, S ;

Eschar, Y ;

Caspi, A ;

Arditi, A ;

Botwin, S ;

Arkavi, L ;

Ziv, M ;

David, D ;

Weisenberg, D ;

Kohanovski, M ;

Meisel, S ;

Rougin, N ;

Yahalom, M ;

Glusman-Vazan, A ;

Markiewitz, W ;

Motlak, D ;

Lessick, J ;

Kagan, G ;

Marmour, A .

CIRCULATION, 2000, 102 (01) :21-27

[7] Fibrates, dyslipoproteinaemia and cardiovascular disease [J].

Watts, GF ;

Dimmitt, SB .

CURRENT OPINION IN LIPIDOLOGY, 1999, 10 (06) :561-574

← 1 →